Prognostic Value Of Urine Neutrophil Gelatinase-Associated Lipocalin In Acute Decompensated Heart Failure: A Systematic Review And Meta-Analysis
Alexander Manguba,Guneesh Uberoi,Anuradha Lala
DOI: https://doi.org/10.1016/j.cardfail.2023.10.231
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Neutrophil gelatinase-associated lipocalin (NGAL) is a widely studied biomarker in various clinical conditions, including cardiovascular diseases. Several studies have investigated its utility as a prognostic marker in acute decompensated heart failure (ADHF), including predicting the development of worsening renal function (WRF) or acute kidney injury (AKI). WRF and AKI are commonly defined using measurement of serum creatinine, which is a marker of glomerular filtration rather than tubular damage. An impetus for studying urinary NGAL (uNGAL) was to find an earlier marker of kidney injury prior to changes in serum creatinine. Importantly, it may also provide additional prognostic information on risk of death and readmission. Methods We systematically searched PubMed, Embase, Scopus, Web of Science, and CINAHL from inception until March 2023. We included studies of adult patients with ADHF that reported uNGAL levels and measured its association with outcomes of WRF/AKI, death, or readmission. We excluded pediatric, animal, or surgical populations, and conference abstracts. Meta-analysis of studies with similar effect measures was done using random effects model. Findings A total of 1694 studies were found, and we screened 1004 after removing 690 duplicates. After initial screening, we reviewed the full text of 37 studies. A total of 24 studies met the inclusion criteria. Most of the studies are observational. Three studies are post hoc analyses of the ROSE-AHF or CARRESS-HF trials, and five are sub-studies of a multicenter cohort (AKINESIS). The studies are marked by differences in design, timing of uNGAL measurement, definition of WRF/AKI, length of follow-up, analysis performed, and adjustment factors used. Six studies (total 1672 patients) evaluated the association of uNGAL with mortality after hospitalization for ADHF using multivariable models. Common adjustment factors include age, sex, systolic blood pressure, renal function (creatinine, BUN, or eGFR), and natriuretic peptide levels. Follow-up ranged from 180 days to over one year. The pooled hazard ratio (HR) for death using multivariable analysis (See Image) is 1.17 (95% CI 0.97, 1.42). Pooled effect sizes for other outcomes based on multivariable analyses are: WRF/AKI (odds ratio) 1.03 (95% CI 1.00, 1.06), and readmission (HR) 1.09 (95% CI, 0.85, 1.40). There is substantial heterogeneity in the studies, with I2 greater than 60-70%. Conclusion In patients with ADHF, urine NGAL does not independently predict development of WRF/AKI or subsequent outcomes (death or readmission).
cardiac & cardiovascular systems